Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Chronic obstructive pulmonary disease: diagnosis and staging

Respiratory · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

New severe breathlessness, SpO2 below the person's target, confusion, cyanosis, chest pain, haemoptysis, unilateral reduced air entry or inability to manage at home may be an exacerbation, pneumonia, pneumothorax, pulmonary embolism or heart failure; assess urgently rather than completing routine diagnostic staging.

Synopsis

Confirm persistent airflow obstruction in the correct clinical context, describe disease impact beyond FEV1, and identify alternative diagnoses, alpha-1 antitrypsin deficiency and complications that change management.

  • Think COPD in adults over 35 with smoking or occupational exposure plus exertional breathlessness, chronic cough, regular sputum, frequent winter bronchitis or wheeze.
  • Confirm with quality-assured post-bronchodilator spirometry showing FEV1/FVC below 0.70 in the appropriate clinical context.
  • A fixed ratio can overdiagnose older adults and miss some younger adults; use the lower limit of normal and diagnostic review when symptoms and ratio disagree.
  • NICE airflow grades use post-bronchodilator FEV1: mild at least 80% predicted, moderate 50-79%, severe 30-49%, very severe below 30%.
  • FEV1 grade does not equal symptom burden or prognosis. Record MRC dyspnoea, exacerbations, admissions, oxygenation, BMI, exercise capacity and comorbidity separately.
  • Obstruction can be asthma, bronchiectasis, post-TB disease or bronchiolitis; a large variability history, atopy/eosinophilia or childhood symptoms may indicate asthma or coexistence.
  • CXR excludes alternative structural disease but does not confirm COPD; CT is targeted to diagnostic uncertainty, disproportionate symptoms, bronchiectasis or procedural/surgical assessment.
  • Test alpha-1 antitrypsin in younger people, minimal smokers, those with a family history or basal-predominant emphysema; confirm abnormal levels with genotype/phenotype specialist pathways.
  • Ask about occupational dusts/fumes and biomass, not only cigarettes; quantify pack-years and offer evidence-based tobacco-dependence treatment at every opportunity.
  • Document the diagnosis as a synthesis: exposure + symptoms + persistent obstruction + impact/phenotype, not 'FEV1 45%' alone.

Key red flags

Alternative or additional disease

Clubbing, focal signs, haemoptysis, very large sputum volume, systemic features, rapid decline or disproportionate hypoxaemia suggests cancer, bronchiectasis, ILD, TB, heart failure or pulmonary vascular disease.

Investigation priorities

01
Post-bronchodilator spirometryFirst step

Confirm persistent airflow obstruction.

Management branches

ConfirmFrom suspicion to documented COPD

Compatible symptoms and exposure history.

  1. Take exposure, symptom, exacerbation, childhood/asthma, occupational and family history; examine for wheeze, hyperinflation, cyanosis, oedema, cachexia, clubbing and cardiac disease.
  2. Perform quality-assured post-bronchodilator spirometry when stable. Confirm persistent obstruction only when FEV1/FVC below 0.70 fits the syndrome; review LLN in borderline or age-discordant cases.
  3. Obtain CXR, FBC, BMI and resting SpO2; add ECG/BNP, CT, full physiology or microbiology when the presentation is atypical or disproportionate.
  4. Document FEV1 grade, MRC score, exacerbation/admission count, smoking status, oxygenation and asthmatic/eosinophilic features as separate management domains.

Key medicines

Nicotine replacement combinationExample: nicotine patch delivering 21 mg/24 h daily for heavier dependence plus a rapid product such as 2 mg gum or lozenge when cravings occur; taper over roughly 8-12 weeks according to response and product directions.Individualise to cigarettes/day, time to first cigarette, pregnancy and cardiovascular context; avoid smoking while using more nicotine than intended and teach correct gum/lozenge technique. Link to behavioural support.
Salbutamol symptom reliever while full plan is established100-200 micrograms inhaled when required, commonly 1-2 actuations of a 100 microgram pMDI; frequency and maximum follow the specific SmPC.Rising use signals poor control or another diagnosis. Tremor, tachycardia and hypokalaemia can occur; ensure technique and do not use response as diagnostic proof.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG115: COPD diagnosis and managementDiagnostic features, spirometry, airflow grading and targeted investigations.
  • NHS England adult breathlessness diagnostic pathwayDifferential assessment and MRC scale.
  • NHS England QOF guidance—COPD diagnostic and review indicatorsQuality-assured post-bronchodilator confirmation and annual impact review.
  • NICE TA1142: dupilumab for uncontrolled COPD with raised eosinophilsCurrent March 2026 phenotype threshold and specialist treatment criteria.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom